David Lorenz, MS

Dave Lorenz specializes in statistical and economic analysis of issues involving pharmaceutical manufacturers, medical device manufacturers, healthcare providers, and other life sciences and healthcare industry participants involved in litigation, government investigations, and merger reviews. Mr. Lorenz has more than a decade of experience supporting counsel and experts through all phases of the litigation—including support of discovery, trial, and settlement negotiations. He also has extensive experience applying machine learning, data visualization, and big data processing techniques to extract insights for clients.

MS, Business Analytics, University of Virginia

BS, Economics, Schreyer Honors College, Penn State University

• In Veeva Systems Inc. v. IQVIA Inc., supported testifying expert and counsel on issues of market definition, market power, theory of harm, and competitive effects concerning the monopolization of data and data management software for pharmaceutical companies.
• In New Jersey Primary Care Association, Inc. v. State of New Jersey Department of Human Services, et al., supported the expert in advising the plaintiff regarding the allocation of settlement proceeds among Federally Qualified Health Centers.
• In In re National Prescription Opiate Litigation, supported testifying experts and counsel with data analysis of marketing and prescribing data to evaluate causation and damages on behalf of a manufacturer defendant concerning allegations of inappropriate marketing of prescription opioids.
• In United States v. Novartis Pharmaceuticals Corp., supported Dr. Eric Gaier and counsel with analysis of marketing, prescribing, and claims data to assess causation and damages on behalf of Novartis in connection with alleged FCA violations associated with alleged kickbacks concerning Novartis’s promotional events for ten self-administered drugs indicated for hypertension or type 2 diabetes.
• Supported Dr. Eric Gaier in United States v. Novartis Pharmaceuticals Corp. and BioScrip, Inc. with analysis of causation, damages, and drug adherence on behalf of Novartis.
• Provided medical device manufacturer facing a government investigation of a diagnostic testing product with statistical analyses. Supported manufacturer in its interactions with the Food and Drug Administration regarding the diagnostic performance of the product.